 HAIFA, Israel, Nov. 18, 2020 GLOBE NEWSWIRE -- Pluristem Therapeutics Inc. Nasdaq:PSTI TASE:PSTI, a leading regenerative medicine company developing a platform of novel biological therapeutic products, today reported the first clinical results for PLX-R18 in humans from its Phase I study evaluating PLX-R18 as a treatment for incomplete hematopoietic recovery following hematopoietic cell transplantation HCT. The initial results consisted of the analysis of the first 19 patients enrolled, and not all patients completed a one year follow up. 